Our Clinical Trials

ViaCyte has the first and only islet cell replacement therapies derived from stem cells in clinical trials for diabetes.

While the discovery of insulin 100 years ago transformed type 1 diabetes from a fatal illness to a chronic illness, it is not a cure. Quality of life challenges and long-term complications remain a constant reality for patients with type 1 diabetes no matter how carefully they manage the disease. ViaCyte’s stem cell-derived islet cell replacement therapies are being developed to treat insulin-requiring diabetes, including type 1 diabetes and potentially certain patients with type 2 diabetes. ViaCyte’s product candidates, PEC-Direct and PEC-Encap, have the potential to relieve patients from the constant management of this disease and thereby provide a functional cure.

In our clinical trials, we are testing for safety and efficacy of the PEC-Encap and PEC-Direct product candidates. We have a number of clinical trials at various sites in the United States, Canada, and Europe. For the most up-to-date information, please visit www.clinicaltrials.gov.

Our clinical trials are supported in part by JDRF, the leading global organization funding type 1 diabetes research. In addition to JDRF, our clinical trials have received funding from California Institute for Regenerative Medicine (CIRM)’s Alpha Clinic, the Sanford Stem Cell Clinical Center, the JDRF Canadian Clinical Trials Network (CCTN), the Stem Cell Network, and Alberta Innovates Health Solutions (AIHS).

If you would like more information, please visit our advocacy partners.